Home>>Signaling Pathways>> Neuroscience>> AChE>>Demecarium Bromide (BC-48)

Demecarium Bromide (BC-48)

Catalog No.GC31190

Demecarium Bromide (BC-48) (BC-48) is a potent cholinesterase inhibitor, with an apparent affinity (Kiapp) of 0.15 μM.

Products are for research use only. Not for human use. We do not sell to patients.

Demecarium Bromide (BC-48) Chemical Structure

Cas No.: 56-94-0

Size Price Stock Qty
10mM (in 1mL DMSO)
$87.00
In stock
5mg
$56.00
In stock
10mg
$82.00
In stock
25mg
$110.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Demecarium Bromide (BC-48) is a potent cholinesterase antagonist, with an apparent affinity (Kiapp) of 0.15 μM[1]. Demecarium Bromide (BC-48) is used as a glaucoma agent[2].

Demecarium Bromide (0.125 and 0.5%) causes long-term miosis and decreases intraocular pressure (IOP) in beagles with both normotensive eyes and inherited glaucoma[1].

[1]. Brown JH, et al. Activation and blockade of cardiac muscarinic receptors by endogenous acetylcholine and cholinesterase inhibitors. J Pharmacol Exp Ther. 1982 Oct;223(1):20-4. [2]. Gum GG, et al. Effect of topically applied demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in beagles with normotensive eyes and beagles with inherited glaucoma. Am J Vet Res. 1993 Feb;54(2):287-93.

Reviews

Review for Demecarium Bromide (BC-48)

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Demecarium Bromide (BC-48)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.